Magnitude Biosciences, a Durham University spinout, has raised $1.3 million to scale VivoScan, a high-throughput platform that screens compounds in living C. elegans nematodes rather than isolated cells. Using hundreds of worms at a time with automated imaging and machine learning, the platform generates whole-organism data in weeks instead of years. For longevity research, where interventions must be judged by their effect on lifespan and healthspan rather than a single molecular endpoint, this compresses one of the field's most persistent timing constraints.
Key Points
- $1.3m raised to scale whole-organism compound screening in nematodes
- Hundreds of worms, imaging and automation replace single-endpoint cell assays
- Whole-lifespan aging data generated in weeks rather than years
Longevity Analysis
Compounds that perform well against isolated molecular targets frequently fail once placed in an intact organism, because the pathways governing energy production, repair and resilience only reveal their interactions when they operate together. Screening in a short-lived animal that shares much of human aging biology reads those integrated signals early, before years and capital are committed to a candidate that cannot hold up across a full lifespan. The practical value for longevity is prioritization: fewer plausible-looking dead ends, and faster identification of interventions whose effects register at the level of whole-organism health rather than a single biomarker.
Original published by Longevity.Technology, by Kyle Umipig.